OUTCOMES
As MEMOTEXT moves forward,
our initiatives are backed not only by results but by
a large body of research.
Outcomes and program metrics are defined
situationally with parameters of acceptable medication
compliance carefully delineated and appropriate to the
health behavior intervention. Additionally, measurement
methods must be valid, reliable, and sensitive to change
throughout an intervention. Adherence to target treatment
is assessed using self-report methods, biochemical measures,
medication counts, and automated refill review strategies.
MEMOTEXT focuses heavily on research and
development on an ongoing basis with 3rd party research
and academia.
Success metrics are defined during stakeholder
analysis and project visioning stages, refined and validated
during the program requirements elicitation phase and
embedded into program analytics dependent on recruitment
channels and program scope.
| Select Projects |
 |
Designed to help ensure optimal results, EXOGEN
CONNECTS provides patients with free treatment reminders
using interactive voice, SMS text messaging and
emails with tips for healthy living. Patients are
better informed, more likely to follow treatment
plans and are on the road to healing. EXOGEN CONNECTS
is easy to join. Easy to use. And it makes compliance
easier to achieve. Visit this treatment compliance
initiative at www.exogenconnects.com
|
 |
As part of a Natural Sciences and
Engineering Research Council of Canada (NSERC) grant
and The George Brown College Research Seed Funding
Program, MEMOTEXT is collaborating with George Brown
College to work hands on with George Brown students
in their respective fields. The program focuses
on identifying patient’s psychological, historical
and literacy levels as barriers to following a Type
2 Diabetes treatment regimen. MEMOTEXT is working
with students from the Information Systems Business
Analysis, and Health Informatics programs; each
bringing their own unique level of expertise to
the project.
|
JOHNS
HOPKINS
University
|
Johns Hopkins study demonstrates 16% increase in patient adherence using MEMOTEXT and Microsoft HealthVault in the first randomized clinical trial of its kind in North America.
The study entitled “The Impact of Automated Dosing Reminders on Medication Adherence Using HealthVault,” was conducted by Johns Hopkins University and funded by the Microsoft HealthVault BeWell Fund.
Preliminary results were presented at the March 2011 annual meeting of American Glaucoma Society and Mobile Health 2011: What Really Works conference at Stanford University.
Of the 428 participants analyzed thus far, the study showed an increase in adherence from 51 to 67% with daily glaucoma therapy using a MEMOTEXT adherence solution integrated with Microsoft HealthVault. A control group with no intervention showed no change in adherence. The study to be published this year demonstrates efficacy of MEMOTEXT solutions integrated with a personal health record.
Study participants received interactive SMS and Voice calls to ensure adherence to glaucoma treatment regimens. See the poster here .
|
 |
AVOTALK
Patients with Multiple Sclerosis (MS) who take
the once-a-week prescription injection AVONEX®
(interferon beta-1a) now benefit from a free and
unique adherence solution. The program, named AVOTALK,
is a telephone reminder service for patients who
are prescribed AVONEX.
With direct links to live nurse-educators at the
MS
Alliance call center, the program provides
support, education and reminders 7X24. |
 |
|
